← Back

AZNAstraZeneca

$160.00-1.66%Real quote · delayedPharma

🏛️ Company factsSEC filings + FINRA official data

short activity above its recent average — bears adding.

Short volume

35.2%

20d avg 27.8% · shorts building

🐋 5%+ ownership filings (last 180d)

The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.

2026-04-28passive (13G)VANGUARD CAPITAL MANAGEMENT LLC

No SEC filings for this ticker (non-US filer or newly listed)

🎯 Market expectations

Expectation reliability Medium · 52/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$2.60Estimate range $2.59 ~ $2.62 · 3 analystsRevisions (4w):↓1

History: actual vs consensusavg -10.4%

Jun 2026$2.63 vs $2.50+5.2%
Mar 2026$2.58 vs $2.57+0.39%
Dec 2025$1.06 vs $2.18-51.38%
Sep 2025$2.38 vs $2.28+4.39%

The takeaway

It has missed by -10.4% on average recently; expectations have been marked down repeatedly.

Analyst estimates, not our forecast · not investment advice

What's moving this stock lately

1 direct · 1 2nd-order · 0 thematic

Ranked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)

#1▲1.28%DirectHUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China9d ago
TAGRISSO (osimertinib) is the backbone of the combination; an expanded first-line market modestly supports AstraZeneca's lung-cancer franchise, though impact is small relative to its scale
Impact chain →
Also named: HCM · MRK · NVS
#2▲0.3%2nd-orderFDA Grants Accelerated Approval to a New Breast Cancer Treatment4d ago
Enhertu leader benefits from signals of a smooth accelerated pathway, though it also faces a new competitor.
Impact chain →
Also named: GILD · PFE · LLY

🕰️ Price × news · engine report card

Drag to pan, scroll to zoom · real daily bars and volume

The 12 engine calls on this chart (hit / miss / pending) are Pro — price and volume only for now▂ volume

📜 Call history (newest first

🔒 Pro only

12 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view

🔒 Pro only

Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.